GD2 CAR T cells against human glioblastoma
Glioblastoma is the most malignant primary brain tumor and is still in need of effective
medical treatment. We isolated patient-derived glioblastoma cells showing high GD2
antigen expression representing a potential target for CAR T strategy. Data highlighted a
robust GD2 CAR antitumor potential in 2D and 3D glioblastoma models associated with a
significant and CAR T-restricted increase of selected cytokines. Interestingly,
immunosuppressant TGF β1, expressed in all co-cultures, did not influence antitumor …
medical treatment. We isolated patient-derived glioblastoma cells showing high GD2
antigen expression representing a potential target for CAR T strategy. Data highlighted a
robust GD2 CAR antitumor potential in 2D and 3D glioblastoma models associated with a
significant and CAR T-restricted increase of selected cytokines. Interestingly,
immunosuppressant TGF β1, expressed in all co-cultures, did not influence antitumor …
GD2 CAR T cells against human glioblastoma
P Malvina, C Chiara, G Giulia, G Giulia… - NPJ Precision …, 2021 - search.proquest.com
Glioblastoma is the most malignant primary brain tumor and is still in need of effective
medical treatment. We isolated patient-derived glioblastoma cells showing high GD2
antigen expression representing a potential target for CAR T strategy. Data highlighted a
robust GD2 CAR antitumor potential in 2D and 3D glioblastoma models associated with a
significant and CAR T-restricted increase of selected cytokines. Interestingly,
immunosuppressant TGF β1, expressed in all co-cultures, did not influence antitumor …
medical treatment. We isolated patient-derived glioblastoma cells showing high GD2
antigen expression representing a potential target for CAR T strategy. Data highlighted a
robust GD2 CAR antitumor potential in 2D and 3D glioblastoma models associated with a
significant and CAR T-restricted increase of selected cytokines. Interestingly,
immunosuppressant TGF β1, expressed in all co-cultures, did not influence antitumor …